TickerFacts.

Company research / BSX

Boston Scientific Corp (BSX)

Build a valuation ↗↓ Download CSV

SEC name BOSTON SCIENTIFIC CORP · CIK 0000885725 · NYSE · Surgical & Medical Instruments & Apparatus

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Boston Scientific Corp reported revenue of $20.07B. Revenue grew 19.9% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $21.00B.

Key ratios (year ended 2025-12-31)

69.0%
Gross margin
18.0%
Operating margin
14.4%
Net margin
11.8%
Return on year-end equity
19.9%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-07

Headquarters locality: Marlborough · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$21.00B$20.07B$16.75B$14.24B$12.68B$11.89B$9.91B$10.73B$9.82B$9.05B$8.39B
Cost of Revenue$6.32B$6.22B$5.26B$4.34B$3.96B$3.71B$3.46B$3.12B$2.81B$2.59B$2.42B
Gross Profit$14.68B$13.85B$11.49B$9.90B$8.73B$8.18B$6.45B$7.62B$7.01B$6.46B$5.96B
R&D Expense$2.15B$2.05B$1.61B$1.41B$1.32B$1.20B$1.14B$1.17B$1.11B$997.00M$920.00M
Operating Income$4.15B$3.61B$2.60B$2.34B$1.65B$1.20B-$80.00M$1.52B$1.51B$1.28B$447.00M
Depreciation & Amortization$1.41B$1.37B$1.27B$1.20B$1.14B$1.09B$1.12B$1.01B$894.00M$844.00M$815.00M
EBITDA$5.57B$4.98B$3.87B$3.54B$2.79B$2.29B$1.04B$2.53B$2.40B$2.13B$1.26B
Net Income$3.67B$2.89B$1.85B$1.59B$698.00M$1.04B-$82.00M$4.70B$1.67B$104.00M$347.00M
EPS (Diluted)n/a$1.94$1.25$1.07$0.45$0.69-$0.08$3.33$1.19$0.08$0.25
Total Assets$45.22B$43.67B$39.40B$35.14B$32.47B$32.23B$30.78B$30.57B$21.00B$19.04B$18.10B
Long-Term Debtn/an/an/an/an/an/an/an/an/a$3.81B$5.42B
Shareholders' Equity$25.17B$24.47B$22.00B$19.53B$17.57B$16.62B$15.33B$13.88B$8.73B$7.01B$6.73B
Cash & Equivalents$539.00M$1.97B$414.00M$865.00M$928.00M$1.93B$1.73B$217.00M$146.00M$188.00M$196.00M
Operating Cash Flow$4.53B$4.53B$3.44B$2.50B$1.53B$1.87B$1.51B$1.84B$310.00M$1.43B$1.18B
Capital Expenditures$904.00M$876.00M$790.00M$711.00M$588.00M$554.00M$376.00M$461.00M$316.00M$319.00M$376.00M
Free Cash Flow$3.62B$3.66B$2.65B$1.79B$938.00M$1.32B$1.13B$1.38B-$6.00M$1.11B$806.00M
Share Repurchasesn/an/an/an/a$0$0$535.00M$0$0n/a$0
Dividends Paidn/an/a$0$28.00M$55.00M$55.00M$28.00M$0$0n/an/a
Shares Outstandingn/an/an/an/an/an/an/a1.39B1.38B1.37B1.36B
Weighted Average Diluted Sharesn/a1.49B1.49B1.46B1.44B1.43B1.42B1.41B1.40B1.39B1.38B
EPS (Basic)n/a$1.96$1.26$1.08$0.45$0.69-$0.08$3.38$1.21$0.08$0.26

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView